tetano
Editor, Senior Moderator
Microbiol Spectr
. 2023 Jun 27;e0482722.
doi: 10.1128/spectrum.04827-22. Online ahead of print. Wnt-Independent SARS-CoV-2 Infection in Pulmonary Epithelial Cells
Alexey Koval[SUP] 1 [/SUP], Jiabin Xu[SUP] 1 [/SUP], Nathalia Williams[SUP] 2 [/SUP], Mirco Schmolke[SUP] 2 [/SUP], Karl-Heinz Krause[SUP] 3 [/SUP], Vladimir L Katanaev[SUP] 1 4 [/SUP]
Affiliations
The Wnt signaling pathway within host cells regulates infections by several pathogenic bacteria and viruses. Recent studies suggested that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on β-catenin and can be inhibited by the antileprotic drug clofazimine. Since clofazimine has been identified by us as a specific inhibitor of Wnt/β-catenin signaling, these works could indicate a potential role of the Wnt pathway in SARS-CoV-2 infection. Here, we show that the Wnt pathway is active in pulmonary epithelial cells. However, we find that in multiple assays, SARS-CoV-2 infection is insensitive to Wnt inhibitors, including clofazimine, acting at different levels within the pathway. Our findings assert that endogenous Wnt signaling in the lung is unlikely required or involved in the SARS-CoV-2 infection and that pharmacological inhibition of this pathway with clofazimine or other compounds is not a universal way to develop treatments against the SARS-CoV-2 infection. IMPORTANCE The development of inhibitors of the SARS-CoV-2 infection remains a need of utmost importance. The Wnt signaling pathway in host cells is often implicated in infections by bacteria and viruses. In this work, we show that, despite previous indications, pharmacological modulation of the Wnt pathway does not represent a promising strategy to control SARS-CoV-2 infection in lung epithelia.
Keywords: SARS-CoV-2; Wnt; Wnt pathway inhibitors; Wnt signaling; clofazimine; drug discovery; lung epithelia.
. 2023 Jun 27;e0482722.
doi: 10.1128/spectrum.04827-22. Online ahead of print. Wnt-Independent SARS-CoV-2 Infection in Pulmonary Epithelial Cells
Alexey Koval[SUP] 1 [/SUP], Jiabin Xu[SUP] 1 [/SUP], Nathalia Williams[SUP] 2 [/SUP], Mirco Schmolke[SUP] 2 [/SUP], Karl-Heinz Krause[SUP] 3 [/SUP], Vladimir L Katanaev[SUP] 1 4 [/SUP]
Affiliations
- PMID: 37367224
- DOI: 10.1128/spectrum.04827-22
The Wnt signaling pathway within host cells regulates infections by several pathogenic bacteria and viruses. Recent studies suggested that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on β-catenin and can be inhibited by the antileprotic drug clofazimine. Since clofazimine has been identified by us as a specific inhibitor of Wnt/β-catenin signaling, these works could indicate a potential role of the Wnt pathway in SARS-CoV-2 infection. Here, we show that the Wnt pathway is active in pulmonary epithelial cells. However, we find that in multiple assays, SARS-CoV-2 infection is insensitive to Wnt inhibitors, including clofazimine, acting at different levels within the pathway. Our findings assert that endogenous Wnt signaling in the lung is unlikely required or involved in the SARS-CoV-2 infection and that pharmacological inhibition of this pathway with clofazimine or other compounds is not a universal way to develop treatments against the SARS-CoV-2 infection. IMPORTANCE The development of inhibitors of the SARS-CoV-2 infection remains a need of utmost importance. The Wnt signaling pathway in host cells is often implicated in infections by bacteria and viruses. In this work, we show that, despite previous indications, pharmacological modulation of the Wnt pathway does not represent a promising strategy to control SARS-CoV-2 infection in lung epithelia.
Keywords: SARS-CoV-2; Wnt; Wnt pathway inhibitors; Wnt signaling; clofazimine; drug discovery; lung epithelia.